On March 25, Ge Longhui | China Biopharmaceutical (01177.HK) announced that the medical imaging product iopromide injection (trade name: polyiodine) developed by the Group has obtained marketing approval from China's State Drug Administration. For diagnostic use, it can be used for intravascular and intra-body imaging.
According to the disclosure, iopromide is a triiodized non-ionic water-soluble X-ray contrast agent with high iodine content and good contrast effect. It is mostly used for computer X-ray tomography (CT) enhancement, arteriography and venography, endoscopic retrograde cholangiopancreatography (ERCP), joint cavity imaging, and other body cavity tests.